Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.48 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.45 |
| ▸ | SCN4A | P35499 | 3/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30255795 | 1.00 | CYP17A1 (0.50) | CYP17A1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL25200778 | 0.82 | HDAC3 (0.47) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL30256312 | 0.79 | HDAC3 (0.50) | CYP17A1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL24028065 | 0.79 | HDAC3 (0.50) | CYP17A1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL24926744 | 0.78 | CYP17A1 (0.41) | CYP17A1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL30256169 | 0.78 | CYP17A1 (0.44) | CYP17A1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL30203099 | 0.78 | CYP17A1 (0.41) | CYP17A1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL24028388 | 0.78 | CYP17A1 (0.44) | CYP17A1HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL24028068 | 0.78 | HDAC3 (0.49) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL30212991 | 0.78 | HDAC3 (0.49) | HDAC3HDAC1HDAC2HDAC10HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2023-06-08 | — | — | US | disclosed |
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2023-06-08 | — | — | US | disclosed |
| CN-115697974-A | Imidazole 3-oxide derivative based ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021229571-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD (IL) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, ADSS2, GLS2 | CYP17A1 752/4885HDAC3 17/4885HDAC1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.